IFNA1 and non-small cell lung carcinoma: In NSCLC patients treated with ceralasertib plus durvalumab in the HUDSON trial peripheral blood RNAseq gene expression analysis showed significant up-regulation of IFN signatures and expanding T-cell clones17.